DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programmeECCO'18 Vienna 2018
1
DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eigth-week induction non-respondersECCO'18 Vienna 2018
1
DOP028: 2nd N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s Disease or Ulcerative ColitisECCO'18 Vienna 2018
1
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s DiseaseECCO'18 Vienna 2018
1
DOP030: The efficacy of home telemonitoring versus conventional follow-up: A randomised controlled trial among teenagers with Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP031: Individualized home-monitoring of disease activity in adult patients with Inflammatory Bowel Disease can be recommended implemented in clinical practiceECCO'18 Vienna 2018
1
DOP032: Crohn’s Disease patients’ perspectives towards de-escalating immunosuppressive therapy: A comparative French and American surveyECCO'18 Vienna 2018
1
DOP033: Trends in epidemiology of Inflammatory Bowel Disease among Jewish Israeli adolescents: A population based studyECCO'18 Vienna 2018
1
DOP034: Assessment of direct healthcare cost drivers of Crohn's Disease in a Dutch population-based cohort study shows a major shiftECCO'18 Vienna 2018
1
DOP036: Ustekinumab for Crohn's Disease: A nationwide real-life observational cohort study (ICC Case Series)ECCO'18 Vienna 2018
1
DOP039: Exploring stoma rates in Crohn’s Disease in the biologic era: A population-based time trend analysisECCO'18 Vienna 2018
1
DOP041: Surgery and hospitalisation in patients with Inflammatory Bowel Disease; 10 years follow-up of a Danish population-based inception cohortECCO'18 Vienna 2018
1
DOP042: Need for ileocaecal resections, but not ileo-colic re-resections, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014ECCO'18 Vienna 2018
1